Nifty
Sensex
:
:
15699.25
52727.98
142.60 (0.92%)
462.26 (0.88%)

Pharmaceuticals & Drugs - Global

Rating :
43/99

BSE: 500257 | NSE: LUPIN

629.40
24-Jun-2022
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 633.80
  • 637.15
  • 621.25
  • 628.80
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1133553
  •  7133.89
  •  1191.55
  •  583.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 28,634.55
  • N/A
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 31,675.07
  • 0.64%
  • 2.36

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.78%
  • 0.74%
  • 8.53%
  • FII
  • DII
  • Others
  • 14.65%
  • 26.99%
  • 2.31%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.91
  • -2.82
  • -3.27

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.92
  • -10.59
  • -0.78

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 3.52
  • -13.61
  • 26.10

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 26.09
  • 21.72
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.54
  • 3.00
  • 3.10

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 18.61
  • 18.61
  • 22.01

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Var%
Dec 21
Dec 20
Var%
Sep 21
Sep 20
Var%
Jun 21
Jun 20
Var%
Net Sales
3,883.03
3,783.10
2.64%
4,160.93
4,017.36
3.57%
4,091.33
3,835.00
6.68%
4,270.19
3,527.86
21.04%
Expenses
3,656.58
3,075.55
18.89%
3,791.10
3,238.62
17.06%
5,415.18
3,253.83
66.42%
3,342.62
3,039.78
9.96%
EBITDA
226.45
707.55
-68.00%
369.83
778.74
-52.51%
-1,323.85
581.17
-
927.57
488.08
90.04%
EBIDTM
5.83%
18.70%
8.89%
19.38%
-32.36%
15.15%
21.72%
13.84%
Other Income
57.05
58.22
-2.01%
34.06
21.17
60.89%
72.81
24.96
191.71%
64.99
43.28
50.16%
Interest
41.47
31.84
30.24%
33.40
30.92
8.02%
34.43
33.62
2.41%
33.47
44.26
-24.38%
Depreciation
327.19
215.72
51.67%
203.43
244.32
-16.74%
919.33
212.73
332.16%
208.76
214.64
-2.74%
PBT
-85.16
518.21
-
167.06
524.67
-68.16%
-2,204.80
359.78
-
750.33
272.46
175.39%
Tax
426.73
54.01
690.09%
-382.00
83.49
-
-109.91
146.70
-
202.33
164.32
23.13%
PAT
-511.89
464.20
-
549.06
441.18
24.45%
-2,094.89
213.08
-
548.00
108.14
406.75%
PATM
-13.18%
12.27%
13.20%
10.98%
-51.20%
5.56%
12.83%
3.07%
EPS
-11.40
10.15
-
12.01
9.66
24.33%
-46.21
4.66
-
11.95
2.36
406.36%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Net Sales
16,405.48
15,162.96
16,836.56
16,751.37
15,804.15
17,494.33
14,139.03
12,770.01
11,286.57
9,641.30
7,082.91
Net Sales Growth
8.19%
-9.94%
0.51%
5.99%
-9.66%
23.73%
10.72%
13.14%
17.06%
36.12%
 
Cost Of Goods Sold
6,481.24
4,854.28
4,962.72
4,436.67
4,733.76
4,660.97
3,893.70
3,806.16
3,485.50
3,221.50
2,364.87
Gross Profit
9,924.24
10,308.68
11,873.84
12,314.70
11,070.39
12,833.36
10,245.33
8,963.85
7,801.07
6,419.80
4,718.04
GP Margin
60.49%
67.99%
70.52%
73.51%
70.05%
73.36%
72.46%
70.19%
69.12%
66.59%
66.61%
Total Expenditure
16,205.48
12,596.08
14,362.21
14,082.44
12,656.64
13,001.19
10,453.68
9,150.42
8,283.78
7,371.41
5,638.20
Power & Fuel Cost
-
414.48
443.17
442.28
433.88
377.86
381.27
362.81
334.29
320.22
268.82
% Of Sales
-
2.73%
2.63%
2.64%
2.75%
2.16%
2.70%
2.84%
2.96%
3.32%
3.80%
Employee Cost
-
2,825.90
2,986.84
2,770.17
2,864.71
2,849.52
2,141.62
1,747.34
1,464.65
1,266.62
969.53
% Of Sales
-
18.64%
17.74%
16.54%
18.13%
16.29%
15.15%
13.68%
12.98%
13.14%
13.69%
Manufacturing Exp.
-
1,945.67
1,852.21
1,731.57
2,087.52
2,270.19
1,766.00
1,320.55
1,129.59
976.51
753.07
% Of Sales
-
12.83%
11.00%
10.34%
13.21%
12.98%
12.49%
10.34%
10.01%
10.13%
10.63%
General & Admin Exp.
-
1,218.42
1,456.46
3,302.60
1,219.96
1,509.56
1,195.98
806.87
810.53
692.06
471.23
% Of Sales
-
8.04%
8.65%
19.72%
7.72%
8.63%
8.46%
6.32%
7.18%
7.18%
6.65%
Selling & Distn. Exp.
-
1,026.40
1,080.45
1,206.60
1,150.61
1,049.48
870.29
835.48
775.26
709.62
647.88
% Of Sales
-
6.77%
6.42%
7.20%
7.28%
6.00%
6.16%
6.54%
6.87%
7.36%
9.15%
Miscellaneous Exp.
-
310.93
1,580.36
192.55
166.20
283.61
204.82
271.21
283.96
184.88
647.88
% Of Sales
-
2.05%
9.39%
1.15%
1.05%
1.62%
1.45%
2.12%
2.52%
1.92%
2.30%
EBITDA
200.00
2,566.88
2,474.35
2,668.93
3,147.51
4,493.14
3,685.35
3,619.59
3,002.79
2,269.89
1,444.71
EBITDA Margin
1.22%
16.93%
14.70%
15.93%
19.92%
25.68%
26.07%
28.34%
26.60%
23.54%
20.40%
Other Income
228.91
136.29
483.76
333.01
150.35
106.51
185.19
239.75
116.48
27.85
14.35
Interest
142.77
140.64
362.98
302.49
204.35
152.53
59.47
9.81
26.65
40.95
35.47
Depreciation
1,658.71
887.41
970.22
846.05
1,085.87
912.23
487.13
434.70
260.97
332.19
227.52
PBT
-1,372.57
1,675.12
1,624.91
1,853.40
2,007.64
3,534.89
3,323.94
3,414.83
2,831.65
1,924.60
1,196.07
Tax
137.15
448.52
1,146.56
901.69
288.46
978.51
1,059.34
970.40
962.15
584.16
308.56
Tax Rate
-9.99%
26.78%
131.36%
59.58%
53.10%
27.68%
31.87%
28.42%
33.98%
30.35%
25.80%
PAT
-1,509.72
1,226.60
-273.72
611.73
247.74
2,549.21
2,255.84
2,403.24
1,836.37
1,314.16
867.65
PAT before Minority Interest
-1,528.40
1,226.60
-273.72
611.73
254.83
2,556.38
2,264.60
2,444.43
1,869.50
1,340.44
887.51
Minority Interest
-18.68
0.00
0.00
0.00
-7.09
-7.17
-8.76
-41.19
-33.13
-26.28
-19.86
PAT Margin
-9.20%
8.09%
-1.63%
3.65%
1.57%
14.57%
15.95%
18.82%
16.27%
13.63%
12.25%
PAT Growth
-223.08%
-
-
146.92%
-90.28%
13.00%
-6.13%
30.87%
39.74%
51.46%
 
EPS
-33.22
26.99
-6.02
13.46
5.45
56.09
49.63
52.88
40.40
28.91
19.09

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Shareholder's Funds
13,803.14
12,536.70
13,742.23
13,577.06
13,497.57
11,163.37
8,874.06
6,931.57
5,204.18
4,012.89
Share Capital
90.74
90.60
90.50
90.42
90.32
90.12
89.90
89.68
89.51
89.33
Total Reserves
13,522.87
12,231.40
13,433.31
13,275.26
13,233.50
10,958.87
8,728.15
6,815.66
5,107.79
3,920.76
Non-Current Liabilities
1,136.03
3,003.18
7,296.41
6,876.13
6,446.96
6,032.39
426.15
507.16
572.87
729.96
Secured Loans
0.33
0.70
358.82
448.03
217.15
5.55
12.50
24.42
37.95
27.76
Unsecured Loans
15.79
1,792.58
6,282.90
5,976.47
5,430.63
5,368.35
89.33
126.54
209.11
405.20
Long Term Provisions
329.49
296.29
370.79
356.85
308.73
190.00
162.03
132.49
112.45
77.02
Current Liabilities
8,436.09
9,225.20
6,129.87
5,095.55
6,120.59
5,061.17
3,729.23
2,629.55
3,006.92
3,120.30
Trade Payables
2,014.44
2,412.30
2,498.18
2,575.40
2,588.90
1,988.82
1,956.06
1,594.13
1,542.88
1,379.28
Other Current Liabilities
2,451.01
3,124.23
1,279.82
1,517.16
657.97
1,001.27
829.76
287.64
381.25
377.17
Short Term Borrowings
3,049.44
2,492.75
1,580.21
451.76
2,304.33
1,745.41
369.15
402.38
726.82
1,046.99
Short Term Provisions
921.20
1,195.92
771.66
551.23
569.39
325.67
574.26
345.40
355.97
316.86
Total Liabilities
23,430.23
24,809.54
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22
8,843.42
7,935.44
Net Block
7,880.76
7,938.11
11,086.71
10,361.99
11,032.93
8,716.96
4,368.19
3,355.60
3,000.17
2,749.66
Gross Block
14,726.75
14,160.50
15,731.88
13,859.86
12,395.30
9,212.07
6,644.59
5,283.90
4,684.21
4,191.84
Accumulated Depreciation
6,845.99
6,222.39
4,645.17
3,497.87
1,362.37
495.11
2,276.40
1,928.30
1,684.04
1,442.18
Non Current Assets
9,443.86
9,396.33
13,361.79
13,379.28
14,146.71
12,401.61
5,221.19
4,034.77
3,700.29
3,593.12
Capital Work in Progress
1,066.26
939.62
1,639.71
2,598.20
2,133.06
2,702.40
551.87
285.90
310.70
434.84
Non Current Investment
78.07
36.07
185.63
26.71
22.00
14.33
2.51
2.06
2.06
2.80
Long Term Loans & Adv.
405.79
409.58
402.61
383.00
950.76
960.22
274.20
372.99
387.36
396.94
Other Non Current Assets
12.98
72.95
47.13
9.38
7.96
7.70
0.32
0.00
0.00
0.00
Current Assets
13,986.37
15,413.21
13,853.58
12,209.54
11,952.93
9,887.40
7,832.35
6,100.45
5,143.13
4,342.32
Current Investments
2,376.81
2,338.25
2,109.86
234.86
2,114.13
2.02
1,655.89
176.41
0.00
0.00
Inventories
4,092.01
3,456.87
3,836.77
3,662.49
3,642.28
3,273.65
2,503.56
2,129.45
1,948.93
1,732.67
Sundry Debtors
4,474.32
5,445.93
5,149.80
5,192.21
4,307.34
4,548.76
2,656.57
2,464.10
2,186.99
1,780.01
Cash & Bank
1,742.46
2,454.30
987.20
1,408.03
698.17
821.75
481.35
797.50
434.88
402.47
Other Current Assets
1,300.77
537.33
777.47
621.30
1,191.01
1,241.22
534.98
532.99
572.33
427.17
Short Term Loans & Adv.
743.88
1,180.53
992.48
1,090.65
657.58
761.78
294.91
275.15
339.67
306.12
Net Current Assets
5,550.28
6,188.01
7,723.71
7,113.99
5,832.34
4,826.23
4,103.12
3,470.90
2,136.21
1,222.02
Total Assets
23,430.23
24,809.54
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22
8,843.42
7,935.44

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Cash From Operating Activity
1,821.76
1,468.84
1,665.97
1,751.19
4,113.51
-382.39
2,733.05
2,003.93
1,250.96
560.04
PBT
1,676.45
876.78
1,517.17
546.81
3,543.14
3,328.84
3,414.83
2,831.65
1,924.60
1,196.07
Adjustment
1,053.31
1,574.29
1,588.41
2,782.23
1,214.74
585.35
356.73
410.50
419.58
258.51
Changes in Working Capital
-192.49
-471.02
-500.19
-1,019.43
504.62
-3,126.44
-94.91
-466.31
-549.35
-580.65
Cash after chg. in Working capital
2,537.27
1,980.05
2,605.39
2,309.61
5,262.50
787.75
3,676.65
2,775.84
1,794.83
873.93
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-715.51
-511.21
-939.42
-558.42
-1,148.99
-1,170.14
-943.60
-771.91
-543.87
-313.89
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,239.58
1,106.99
-3,282.47
469.87
-2,527.44
-6,961.71
-1,054.51
-858.54
-521.86
-741.25
Net Fixed Assets
-693.00
-481.49
-462.56
-1,394.31
-876.24
480.96
-416.45
-309.36
-324.79
-389.71
Net Investments
-2,106.15
-67.96
-2,025.62
1,551.07
-3,173.10
-296.59
-2,280.57
-475.62
-0.75
-6.41
Others
1,559.57
1,656.44
-794.29
313.11
1,521.90
-7,146.08
1,642.51
-73.56
-196.32
-345.13
Cash from Financing Activity
-1,885.27
-890.58
744.13
-1,492.10
433.18
5,836.38
-196.89
-857.11
-662.82
108.86
Net Cash Inflow / Outflow
-1,303.09
1,685.25
-872.37
728.96
2,019.25
-1,507.72
1,481.65
288.28
66.28
-72.35
Opening Cash & Equivalents
2,229.31
544.06
1,416.43
687.47
780.22
2,095.06
606.62
310.93
244.65
295.88
Closing Cash & Equivalent
926.22
2,229.31
544.06
1,416.43
2,799.47
780.22
2,108.43
606.62
310.93
244.65

Financial Ratios

Consolidated /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Book Value (Rs.)
300.06
272.01
298.87
295.64
295.04
245.21
196.17
154.00
116.13
89.78
ROA
5.09%
-1.05%
2.32%
0.99%
10.57%
12.82%
21.08%
19.70%
15.98%
12.40%
ROE
9.46%
-2.12%
4.55%
1.91%
20.98%
22.80%
31.09%
30.89%
29.12%
24.35%
ROCE
9.70%
6.02%
8.45%
3.54%
18.53%
24.38%
40.30%
40.97%
32.70%
24.40%
Fixed Asset Turnover
1.96
2.10
1.93
2.07
1.63
1.80
2.16
2.28
2.19
1.99
Receivable days
64.06
61.62
66.11
63.76
91.82
92.24
72.65
74.67
74.61
77.76
Inventory Days
48.75
42.41
47.94
49.03
71.70
73.96
65.73
65.48
69.24
75.12
Payable days
161.68
65.89
68.49
68.56
60.60
63.20
64.43
63.78
63.76
64.11
Cash Conversion Cycle
-48.88
38.14
45.56
44.23
102.92
103.00
73.94
76.37
80.10
88.76
Total Debt/Equity
0.35
0.51
0.63
0.53
0.60
0.65
0.06
0.09
0.22
0.41
Interest Cover
12.91
3.40
6.00
3.66
24.18
56.89
349.10
107.25
48.00
34.72

News Update:


  • Lupin Diagnostics launches first regional reference laboratory in Patna
    15th Jun 2022, 15:27 PM

    By establishing a presence in Patna, the company now looks forward to making a deeper foray into Bihar

    Read More
  • Lupin gets tentative approval for Ivacaftor Tablets from USFDA
    8th Jun 2022, 14:09 PM

    This product will be manufactured at Lupin’s Nagpur facility in India

    Read More
  • Lupin reports consolidated net loss of Rs 512 crore in Q4
    19th May 2022, 11:07 AM

    The company has reported a standalone net loss of Rs 35.89 crore for the quarter ended March 31, 2022

    Read More
  • Lupin - Quarterly Results
    18th May 2022, 20:33 PM

    Read More
  • Lupin’s arm recalls Losartan Potassium tablets in US market
    16th May 2022, 10:35 AM

    The company is recalling the affected lot due to ‘CGMP’

    Read More
  • Lupin gets approval from USFDA for Pregabalin Capsules
    6th May 2022, 17:52 PM

    The product will be manufactured at Lupin's facility in Aurangabad, India

    Read More
  • Lupin gets nod from USFDA for Iloperidone tablets
    6th May 2022, 17:00 PM

    The product will be manufactured at Lupin's facility in Goa

    Read More
  • Lupin’s step-down subsidiary launches reference laboratory in Guwahati
    29th Apr 2022, 15:34 PM

    The expansion is in line with Lupin Diagnostics’ strategy to expand its presence across India and increase access to quality testing

    Read More
  • Lupin enters into strategic partnership with Yabao Pharmaceutical
    27th Apr 2022, 10:45 AM

    The demand for high quality pediatric medicines has been growing rapidly in China as a result of the government’s support and policy measures

    Read More
  • Lupin partners with Flutura Business Solutions
    21st Apr 2022, 15:35 PM

    A digital data foundation will host data for all of Lupin's operational processes

    Read More
  • Lupin gets tentative approval from USFDA for Tenofovir Alafenamide tablets
    18th Apr 2022, 14:44 PM

    This product will be manufactured at Lupin's Nagpur facility in India

    Read More
  • Lupin gets USFDA nod for Desvenlafaxine Extended-Release Tablets
    18th Apr 2022, 11:05 AM

    The product will be manufactured at Lupin’s facility in Goa, India

    Read More
  • Lupin launches Merzee capsules in United States
    7th Apr 2022, 15:36 PM

    Slayback had earlier launched this product in the US in February 2021

    Read More
  • Lupin completes acquisition of brands from Anglo-French Drugs & Industries
    7th Apr 2022, 11:58 AM

    The acquisition of the AFDIL brands takes Lupin further in shaping its portfolio to emerge as a leading pharmaceutical company in India

    Read More
  • Lupin enters into licensing agreement with Alvion
    5th Apr 2022, 12:59 PM

    The company is committed to providing new affordable treatment options to healthcare providers and patients

    Read More
  • Lupin signs definitive agreement with Anglo-French Drugs & Industries
    2nd Apr 2022, 10:11 AM

    The company has signed definitive agreement for acquiring a portfolio of brands

    Read More
  • USFDA concludes inspection at Lupin’s New Jersey facility
    1st Apr 2022, 10:11 AM

    The inspection closed with thirteen observations

    Read More
  • Lupin gets approval from USFDA for Sildenafil for oral suspension
    24th Mar 2022, 14:53 PM

    Sildenafil for Oral Suspension, 10 mg/mL (RLD Revatio) had estimated annual sales of $66 million in the US

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.